961.385(2m)(2m)
961.385(2m)(a)(a) The rules promulgated under sub. (2) may not require that a record submitted to the board before 2 years after April 9, 2014, contain the name recorded under s. 450.11 (1b) (bm).
961.385(2m)(b)(b) After consultation with representatives of licensed pharmacists and pharmacies, and subject to the approval of the secretary of safety and professional services, the board may delay the requirement that a record submitted to the board contain the name recorded under s. 450.11 (1b) (bm) for an additional period beyond the date specified in par. (a).
961.385(3)(3)
961.385(3)(a)(a) A pharmacy, pharmacist, or practitioner is immune from civil or criminal liability or professional discipline arising from the pharmacy’s, pharmacist’s, or practitioner’s compliance in good faith with this section or with rules promulgated under this section.
961.385(3)(b)(b) Nothing in this section may be construed to require a pharmacy or pharmacist to obtain, before dispensing a monitored prescription drug to a patient, information about the patient that has been collected pursuant to the program established under sub. (2).
961.385(4)(4)Records generated under the program under this section are not subject to inspection or copying under s. 19.35.
961.385(5)(5)
961.385(5)(a)(a) Beginning with the 3rd calendar quarter of 2016, no later than 30 days after the end of each calendar quarter, the board shall conduct a review of the program under this section to evaluate the actual outcomes of the program compared with projected outcomes, as determined by the board. The board’s review shall include an evaluation of all of the following:
961.385(5)(a)1.1. The satisfaction with the program of pharmacists, pharmacies, practitioners, and other users of the program.
961.385(5)(a)2.2. The program’s impact on referrals of pharmacists, pharmacies, and practitioners to licensing or regulatory boards for discipline and to law enforcement agencies for investigation and possible prosecution.
961.385(5)(b)(b) This subsection does not apply after October 30, 2025.
961.385(6)(6)Beginning with the 3rd calendar quarter of 2016, no later than 30 days after the end of each calendar quarter, the board shall provide a report to the department of safety and professional services that includes all of the following:
961.385(6)(a)(a) The results of the board’s review under sub. (5). This paragraph does not apply after October 30, 2025.
961.385(6)(b)(b) An assessment of the trends and changes in the use of monitored prescription drugs in this state.
961.385(6)(c)(c) The number of practitioners, by profession, and pharmacies submitting records to the board under the program in the previous quarter.
961.385(6)(d)(d) A description of the number, frequency, and nature of submissions by law enforcement agencies under s. 961.37 (3) (a) in the previous quarter.
961.385(6)(e)(e) A description of the number, frequency, and nature of requests made in the previous quarter for disclosure of records generated under the program.
961.385(6)(f)(f) The number of individuals receiving prescription orders from 5 or more practitioners or having monitored prescription drugs dispensed by 5 or more pharmacies within the same 90-day period at any time over the course of the program.
961.385(6)(g)(g) The number of individuals receiving daily morphine milligram equivalents of 1 to 19 milligrams, 20 to 49 milligrams, 50 to 99 milligrams, and 100 or more milligrams in the previous quarter.
961.385(6)(h)(h) The number of individuals to whom both opioids and benzodiazepines were dispensed within the same 90-day period at any time over the course of the program.
961.385(7s)(7s)
961.385(7s)(a)(a) The board may contract with an analytics firm to augment the program under this section with an analytics platform that provides data integration, advanced analytics, and alert management capabilities to detect problematic behaviors of practitioners, pharmacies, pharmacists, and patients.
961.385(7s)(b)(b) If the board augments the program under this section as specified in par. (a), the goals of that augmentation shall include all of the following:
961.385(7s)(b)1.1. Allowing the board, with the assistance of the analytics firm, to identify past patterns of abuse, addiction, or criminal activity.
961.385(7s)(b)2.2. Proactively improving painkiller prescribing, informing clinical practice, and protecting patients at risk.
961.385(7s)(b)3.3. Measuring program outcomes at an individual level to minimize the abuse of monitored prescription drugs in this state.
961.385(7s)(c)(c) For purposes of this subsection, the board may disclose records generated under the program to an analytics firm with which the board contracts.
961.385 HistoryHistory: 2009 a. 362; 2011 a. 260 s. 81; 2013 a. 3, 20, 124, 199; 2015 a. 55 ss. 4477, 4737f to 4731k; Stats. 2015 s. 961.385; 2015 a. 195, 266, 267, 268; 2017 a. 59, 262; 2019 a. 121; 2021 a. 222.